Entheon Biomedical Management

Management criteria checks 4/4

Entheon Biomedical's CEO is Timothy Ko, appointed in Jun 2019, has a tenure of 4.92 years. total yearly compensation is CA$130.00K, comprised of 100% salary and 0% bonuses, including company stock and options. directly owns 15.8% of the company’s shares, worth CA$231.00K. The average tenure of the management team and the board of directors is 3.3 years and 3.2 years respectively.

Key information

Timothy Ko

Chief executive officer

CA$130.0k

Total compensation

CEO salary percentage	100.0%
CEO tenure	4.9yrs
CEO ownership	15.8%
Management average tenure	3.3yrs
Board average tenure	3.2yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Timothy Ko's remuneration changed compared to Entheon Biomedical's earnings?
Date	Total Compensation	Salary	Company Earnings
Feb 29 2024	n/a	n/a	-CA$279k
Nov 30 2023	n/a	n/a	-CA$300k
Aug 31 2023	n/a	n/a	-CA$470k
May 31 2023	n/a	n/a	CA$300k
Feb 28 2023	n/a	n/a	-CA$614k
Nov 30 2022	CA$130k	CA$130k	-CA$2m
Aug 31 2022	n/a	n/a	-CA$3m
May 31 2022	n/a	n/a	-CA$5m
Feb 28 2022	n/a	n/a	-CA$7m
Nov 30 2021	CA$134k	CA$134k	-CA$8m

Compensation vs Market: Timothy's total compensation ($USD94.47K) is below average for companies of similar size in the Canadian market ($USD174.31K).

Compensation vs Earnings: Timothy's compensation has been consistent with company performance over the past year.

CEO

Timothy Ko (37 yo)

4.9yrs

Tenure

CA$130,000

Compensation

Mr. Timothy Ko is the Founder of Entheon Holdings Corp. (formerly, Entheon Biomedical Corp. and MPV Exploration Inc.) and has been its Chief Executive Officer since June 2019. Mr. Ko serves as the Presiden...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Timothy Ko	President	4.9yrs	CA$130.00k	15.8% CA$ 231.0k
Soo-Whan Kim	Interim Chief Financial Officer	1.3yrs	no data	no data
Brian Jahns	Chief Business Officer	3.3yrs	no data	no data
Kelly Pladson	Corporate Secretary	no data	no data	no data

3.3yrs

Average Tenure

Experienced Management: ENBI's management team is considered experienced (3.3 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Timothy Ko	President	3.5yrs	CA$130.00k	15.8% CA$ 231.0k
Michael J. Walker	Scientific Advisor	no data	no data	no data
Dennis McKenna	Scientific Advisor	no data	no data	no data
Matthew Johnson	Scientific Advisor	no data	no data	no data
Robin Carhart-Harris	Scientific Advisor	no data	no data	no data
Andrew Hegle	Director	3.5yrs	CA$120.00k	0.11% CA$ 1.7k
Christopher Gondi	Independent Director	3.5yrs	CA$24.00k	0.56% CA$ 8.3k
Christopher Timmermann	Scientific Advisor	no data	no data	no data
Nancy Maher	Special Advisor of Data Science & Regulatory Affairs	3.2yrs	no data	no data
Andrew Greenshaw	Scientific Advisor	2.8yrs	no data	no data
David Erritzoe	Scientific Advisor	2.8yrs	no data	no data
Henry Kranzler	Member of Advisory Board	2.4yrs	no data	no data

3.2yrs

Average Tenure

44yo

Average Age

Experienced Board: ENBI's board of directors are considered experienced (3.2 years average tenure).

Entheon Biomedical Management

Management criteria checks 4/4

Key information

Recent management updates

Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023

Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer

Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023

Entheon Biomedical Corp. Announces CFO Changes

High number of new and inexperienced directors

High number of new and inexperienced directors

Recent updates

First quarter 2024 earnings released: CA$0.013 loss per share (vs CA$0.016 loss in 1Q 2023)

New minor risk - Shareholder dilution

Entheon Biomedical Corp. announced that it has received CAD 0.1475 million in funding

Entheon Biomedical Corp. announced that it expects to receive CAD 0.1475 million in funding

Full year 2023 earnings released: CA$0.051 loss per share (vs CA$0.35 loss in FY 2022)

Entheon Biomedical Corp., Annual General Meeting, Dec 29, 2023

Entheon Biomedical Corp. Announces Termination of Andrew Hegle as Chief Science Officer

First quarter 2023 earnings released: CA$0.002 loss per share (vs CA$0.032 loss in 1Q 2022)

Entheon Biomedical Corp., Annual General Meeting, Apr 19, 2023

Entheon Biomedical Corp. Announces CFO Changes

High number of new and inexperienced directors

Entheon Biomedical Corp. Closes Patient Enrolment in its Clinical Research Study EBIQ-101

High number of new and inexperienced directors

Entheon Biomedical Corp. announced that it expects to receive CAD 3 million in funding

Entheon Biomedical Corp. Announces EBIQ-101 First-Patient Dose

Entheon Biomedical Corp. Announces the Approval of DMT Clinical Trial

Entheon Biomedical Corp. Announces the Submission of the Regulatory Package for Its Upcoming Phase 1 Clinical Trial

High number of new and inexperienced directors

Entheon Biomedical Provides Update on Clinical and Preclinical DMT Programs

Entheon Biomedical Corp. Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine

New 90-day low: CA$0.72

Entheon Biomedical Corp. Announces Nancy Maher as Special Advisor of Data Science and Regulatory Affairs

Entheon Biomedical Announces Ethics Approval for in Vivo DMT Study

Entheon Biomedical Corp. Appoints Dr. Brian Jahns to the Role of Chief Business Officer

Entheon Biomedical Corp. to Be Included in First North American Psychedelic ETF

Entheon Biomedical Partners with Divergence Neuro Technologies Inc. for Predictive Biomarker Platform Development

Entheon Biomedical Corp. (CNSX:ENBI) acquired HaluGen Life Sciences Inc. for CAD 4.2 million.

Entheon Biomedical Corp. announced that it has received CAD 3.214515 million in funding

Entheon Biomedical Corp. announced that it has received CAD 3.174374 million in funding

Entheon Biomedical Announces Dmt Drug Supply Agreement with Psygen Labs Inc. Completion of Initial Dmt Research Drug Batch and Exercise of Warrants

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age